Avantor (AVTR)
(Delayed Data from NYSE)
$25.57 USD
-0.01 (-0.04%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $25.55 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVTR 25.57 -0.01(-0.04%)
Will AVTR be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for AVTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVTR
Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio
BLCO or AVTR: Which Is the Better Value Stock Right Now?
AVTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pediatrix Medical Group, Inc. (MD) Up 11% Since Last Earnings Report: Can It Continue?
BLCO or AVTR: Which Is the Better Value Stock Right Now?
New Strong Sell Stocks for February 20th
Other News for AVTR
Unusually active option classes on open March 26th
Ingersoll-Rand's Dover deal not a threat to bioprocessing space, says KeyBanc
Buy Rating on Avantor: Strategic Positioning and Market Underestimation Set Stage for Financial Upswing
Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs
Bio-Techne and Qiagen had the biggest increase in short interest levels last month - Baird